Sentences with phrase «of the vaccine research center»

The team was led by Barton Haynes, M.D., director of the Duke Center for HIV / AIDS Vaccine Immunology - Immunogen Discovery (CHAVI - ID) and the Duke Human Vaccine Institute, and John Mascola, M.D., director of the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

«It's a nice tool to have in our arsenal,» says virologist Gary Nabel, director of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases in Bethesda, Maryland.

He teamed up with Robert Seder of the Vaccine Research Center (VCR) at the National Institute of Allergy and Infectious Diseases in Bethesda, Maryland, and scientists at other labs to test immune responses to the vaccine in animals.

However, widespread vaccination «is going to be hard to justify,» argues Gary Nabel, director of the Vaccine Research Center at the National Institutes of Health in Bethesda, Md..

Now that I am part of a Vaccine Research Center (VRC) vaccine study, it enhances that altruistic feeling even more, knowing that my participation may someday save millions of lives.

Not exact matches

Dr. Larry Corey, Principal Investigator, HIV Vaccine Trials Network; Past President and Director, Fred Hutchinson Cancer Research Center Dr. Diane Havlir, Professor of Medicine, University of California, San Francisco Moderator: Siobhan O'Connor, Time Magazine

At 10:30 a.m., U.S. Senate Minority Leader U.S. Chuck Schumer will urge the U.S. Department of Health and Human Services to increase research, vaccine development and treatment strategies to help stamp out tick - borne diseases like Lyme disease, Albany Medical Center, B Entry, Patient Pavilion, Floor E, corner of Myrtle Avenue and New Scotland Avenue, Albany.

In the US, for example, the National Institute of Allergy and Infectious Diseases (NIAID) in Bethesda, Maryland, is a hub for HIV research, and its Vaccine Research Center continues to focus on HIV in preference to other dresearch, and its Vaccine Research Center continues to focus on HIV in preference to other dResearch Center continues to focus on HIV in preference to other diseases.

Center for Vaccine Research, School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA.

«The best explanation for what we are seeing is that frequently, after exposure to HIV, a few cells in the genital tract are infected, without establishment of a systemic infection,» says senior investigator Eric Hunter, PhD, professor of pathology and laboratory medicine at Emory University School of Medicine, Emory Vaccine Center, and Yerkes National Primate Research Center.

«Even with the new immunological studies, we can't tell what's special about the whole - cell vaccine that makes it better,» says Kathryn Edwards, the director of the Vanderbilt University School of Medicine Vaccine Research vaccine that makes it better,» says Kathryn Edwards, the director of the Vanderbilt University School of Medicine Vaccine Research Vaccine Research Center.

Koff says the next milestone will be later stage clinical testing of a vaccine developed by the federally funded National Institutes of Health Vaccine Research Center, which should begin nexvaccine developed by the federally funded National Institutes of Health Vaccine Research Center, which should begin nexVaccine Research Center, which should begin next year.

Now a research team, led by investigators at the Duke Human Vaccine Institute and the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID), has tracked rare potent antibodies in an HIV - infected individual and determined sequential structures that point to how they deresearch team, led by investigators at the Duke Human Vaccine Institute and the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID), has tracked rare potent antibodies in an HIV - infected individual and determined sequential structures that point to how they deResearch Center of the National Institute of Allergy and Infectious Diseases (NIAID), has tracked rare potent antibodies in an HIV - infected individual and determined sequential structures that point to how they developed.

«Based on epidemiological studies, the 9vHPV vaccine could prevent approximately 90 percent of cervical cancer, 90 percent of HPV - related vulvar and vaginal cancer, 70 to 85 percent of high - grade cervical disease in females, and approximately 90 percent of HPV - related anal cancer and genital warts in males and females worldwide,» explained Anna R. Giuliano, Ph.D., Director of the Center for Infection Research in Cancer at Moffitt.

«We could visualize this complex dance between the virus and the antibody and understand exactly how the virus was teaching the antibody to be a broadly neutralizing antibody,» said Peter D. Kwong, Ph.D., chief of the Structural Biology Section at the NIAID Vaccine Research Center.

Maria Elena Bottazzi leads the research, education and administration efforts of the school, is a Professor of Pediatric Tropical Medicine and the Deputy Director for the Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development.

The advantage of Novavax's approach is that a vaccine can be made rapidly and in high volume, compared with the egg - based approach that's used today, says Ted Ross, an associate professor of microbiology and molecular genetics at the University of Pittsburgh's Center for Vaccine Researchvaccine can be made rapidly and in high volume, compared with the egg - based approach that's used today, says Ted Ross, an associate professor of microbiology and molecular genetics at the University of Pittsburgh's Center for Vaccine ResearchVaccine Research (CVR).

Healthy adults mounted strong immune responses after receiving an investigational whole inactivated Zika virus vaccine, according to interim analyses of three Phase 1, placebo - controlled, double - blind trials conducted at Beth Israel Deaconess Medical Center (BIDMC), Walter Reed Army Institute of Research (WRAIR), and Saint Louis University School of Medicine.

The research, led by a scientist at the University of Maryland School of Maryland (UM SOM) Center for Vaccine Development (CVD), was published recently in the journal Proceedings of the National Academy of Sciences.

A team of scientists at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases, part of NIH, created VRC07 - αCD3 under the leadership of VRC Director John R. Mascola, M.D.; former VRC Director Gary J. Nabel, M.D., Ph.D.; and Richard A. Koup, M.D., VRC deputy director and chief of its immunology laboratory.

Despite years of trying, scientists still haven't created an HIV vaccine that can protect people against the virus, says Alan Aderem, a biologist at the Center for Infectious Disease Research in Seattle.

The multi-center study enrolled 31,989 participants from 126 research centers in the U.S. and Canada during the 2011 - 2012 and 2012 - 2013 influenza seasons in the Northern Hemisphere in order to compare the high - dose trivalent vaccine versus the standard - dose trivalent vaccine in adults over 65 years of age.

«We've shown that a specific type of these cells, known as follicular helper T (Tfh) cells are not only necessary, but are a limiting factor that differentiates between an average and a potent antibody response to HIV,» says Crotty, a scientific collaborator with the Center for HIV / AIDS Vaccine Immunology & Immunogen Discovery (CHAVI - ID), a major research consortium led by The Scripps Research Inresearch consortium led by The Scripps Research InResearch Institute.

There's a new cancer vaccine center here in Brisbane; we have a lot of strength in vaccine research.

By studying healthy people, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center, part of the NIH, and colleagues from King's College London have created a reference resource for other scientists.

Trials of the vaccine therapy are planned to start later this year at Massachusetts General Hospital in Boston, Johns Hopkins Medical Center in Baltimore, the Queensland Institute of Medical Research (QIMR) in Brisbane and the Royal Netherlands Cancer Institute in Amsterdam.

This makes the development of an effective vaccine to protect against infection, as well as antiviral therapy to combat already - existing infections, particularly challenging,» says Dr. Grant Hansman, a virologist who leads the CHS Research Group on Noroviruses at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and Heidelberg University.

One goal of the study is to demonstrate the prevalence of H. influenzae in the region, explains Joel Ward, director of the Center for Vaccine Research at the University of California, Los Angeles, and scientific adviser to IVI.

«An RSV vaccine with this M2 - 2 deletion could tip the balance toward a better immune response, which is what we predicted based on earlier laboratory studies,» says study leader Ruth A. Karron, MD, director of the Center for Immunization Research and a professor in the Department of International Health at the Bloomberg School.

President Barack Obama gave a talk at the NIH Clinical Center and then toured the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center.

The molecular details of our discovery will facilitate the design of new drugs and new vaccines,» said Alexis Kaushansky, PhD, an assistant professor at the Center for Infectious Disease Research.

The research was led by the paper's senior author, James Crowe Jr., M.D., the Ann Scott Carrell Professor and director of the Vanderbilt Vaccine Center.

If we can do that, then we can make flu vaccines that would be even more effective than the current vaccine,» said Professor Derek Smith from the University of Cambridge, one of the two leaders of the research, together with Professor Ron Fouchier from Erasmus Medical Center in The Netherlands.

The Walter Reed Army Institute of Research (WRAIR) and collaborators at the Beth Israel Deaconess Medical Center and Harvard Medical School have completed a promising preclinical study of two Zika vaccine candidates that suggests that an effective human vaccine will be achievable.

One, described in Nature Communications today, was conducted by a team from the Vaccine Research Center at the U.S. National Institute of Allergy and Infectious Diseases (NIAID) in Bethesda, Maryland.

«We thought we would need five different sets of vaccines or five different (drugs),» said James Crowe Jr., M.D., the Ann Scott Carrell Professor and director of the Vanderbilt Vaccine Center, who led Vanderbilt's end of the research.

Regulatory affairs is the name of the game at the FDA, in Washington, D.C., and the specialized aspect of reviewing and evaluating drugs or vaccines means there's significant training after hire, says Kathryn Carbone, associate director for research at the Center for Biologics Evaluation and Researchresearch at the Center for Biologics Evaluation and ResearchResearch (CBER).

«The discovery of this new antibiotic was an unexpected result of basic research on HIV proteins,» said senior author Ronald Montelaro, Ph.D., professor and co-director of Pitt's Center for Vaccine Researcresearch on HIV proteins,» said senior author Ronald Montelaro, Ph.D., professor and co-director of Pitt's Center for Vaccine ResearchResearch (CVR).

«This basically changes our whole view of the pathogenesis of HIV infection,» says Daniel Douek, chief of the Human Immunology Section at the National Institutes of Health's Vaccine Research Center.

«The pace of preclinical and early clinical development for Zika vaccines is unprecedented,» said Barouch, corresponding author and director of the Center for Virology and Vaccine Research at BIDMC.

«This is an important demonstration of the possibilities opened up for immunotherapy by DMAb technology to direct in vivo production of antibodies of major relevance to human cancer,» said David B. Weiner, Ph.D., executive vice president of The Wistar Institute, director of The Wistar Institute Vaccine & Immunotherapy Center, W.W. Smith Charitable Trust Professor in Cancer Research, and senior author of the study.

A lab at the center of a longstanding controversy about dangerous virus research has engineered heartier influenza viruses that could streamline vaccine production.

«Many physicians reported tension between the need to build trust with families by being willing to compromise on the schedule while simultaneously feeling they were putting children at risk and causing them unnecessary pain by spreading out vaccines on multiple visits,» writes Allison Kempe, MD, MPH, professor of pediatrics and director of ACCORDS (Adult and Child Center for Health Outcomes Research and Delivery Science) at the University of Colorado School of Medicine and Children's Hospital Colorado.

«We previously showed that adenovirus vector - based HIV - 1 vaccine candidates offered partial protection against SIV when given alone,» said lead author Dan H. Barouch, M.D., Ph.D., director of the Center for Virology and Vaccine Research at BIDMC and professor of medicine at Harvard Medical vaccine candidates offered partial protection against SIV when given alone,» said lead author Dan H. Barouch, M.D., Ph.D., director of the Center for Virology and Vaccine Research at BIDMC and professor of medicine at Harvard Medical Vaccine Research at BIDMC and professor of medicine at Harvard Medical School.

In their report published in Cancer Immunology Research, a team from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH) describes how adding AMD3100 (plerixafor)-- previously approved for the stimulation of stem cell production prior to bone marrow transplantation — to their investigational drug VIC - 008 more than doubled the animals» survival time.

Public health policy and research must overcome several barriers to developing vaccines for pregnant women, say authors Saad B. Omer, MBBS, PhD, professor of global health, epidemiology and pediatrics at Emory University and Richard H. Beigi, MD, MSc, associate professor of obstetrics, gynecology and reproductive sciences at the University of Pittsburgh Medical Center and chief medical officer at Magee - Womens Hospital of UPMC.

Janardan Pandey, Ph.D., an immunogeneticist specializing in immunoglobulin GM genes at the Medical University of South Carolina, helped monitor for immune responses that could limit the effectiveness of the broadly neutralizing antibody VRC01 in a phase 1 trial of that antibody in HIV - infected individuals led by a team at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

But Michael Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota in Minneapolis, says authorities should have been prepared to deploy the vaccine more quickly.

Dr. John Mascola is Director of the Dale and Betty Bumpers Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), U.S. National Institutes of Health.

The Statens Serum Institut (SSI) Center of Vaccine Research is internationally recognised for its vaccine research and clinical piVaccine Research is internationally recognised for its vaccine research and clinical pResearch is internationally recognised for its vaccine research and clinical pivaccine research and clinical presearch and clinical pipeline.